To study concordance and discordance between SPECT and PET and compare the diagnostic performance of cardiac Rubidium-82 perfusion PET and technetium-99m SPECT MPI in a cohort of high-risk patients who have a undergone SPECT myocardial perfusion…
ID
Source
Brief title
Condition
- Coronary artery disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Concordance, discordance, sensitivity and specificity of SPECT and PET
Secondary outcome
nvt
Background summary
Myocardial perfusion imaging (MPI) remains important in the diagnostic and
prognostic evaluation of patients with (suspected) coronary artery disease
(CAD). During decades of experience, single photon emission computed tomography
(SPECT) has been well evaluated for this purpose. However, several limitations
of SPECT remain, which include underestimating of the degree of ischemia in
three vessel or left main CAD and the presence of attenuation artefacts leading
to both false negative and false positive scans. Compared with SPECT, cardiac
perfusion PET imaging with Rubidium82 offers several general advantages: higher
resolution, better sensitivity and specificity, robust attenuation correction
and the possibility of quantifying myocardial blood flow. Although there are
older studies suggesting that PET has a higher accuracy than SPECT in the
diagnosis of CAD, the potential clinical added value of PET over SPECT has not
been determined in a head-to-head comparison study, especially not comparing
PET with the performance of the newest generation of CZT dedicated cardiac
SPECT scanners such as present in Isala.
Study objective
To study concordance and discordance between SPECT and PET and compare the
diagnostic performance of cardiac Rubidium-82 perfusion PET and technetium-99m
SPECT MPI in a cohort of high-risk patients who have a undergone SPECT
myocardial perfusion study.
Study design
Single centre diagnostic efficacy study.
Study burden and risks
Additional PET scanning comprises one extra visit of 1 hr visit to the nuclear
medicine department at the Isala hospital in Zwolle, an additional stress
procedure using regadenoson and an additional radiation dose of approximately 3
mSv.
Dokter van Heesweg 2
Zwolle 8025AB
NL
Dokter van Heesweg 2
Zwolle 8025AB
NL
Listed location countries
Age
Inclusion criteria
Have undergone SPECT evaluation
CAC >100
Have provided written informed consent
Exclusion criteria
No informed consent obtained
Patients with inintolerance of adenosine or regadenoson as stress agents (rare)
Unable to undergo PET imaging
Age < 18 years
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL53333.075.15 |